Qilu Pharmaceutical Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Jinan China (1958)
Status: No NME R&D (1958)

Organization Overview

First Clinical Trial
2013
NCT01931943
First Marketed Drug
2014
ondansetron (zofran)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

QILU | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical (Hainan) Co., Ltd. | QILU PHARM CO LTD | QILU PHARM HAINAN | QILU TIANHE | Shandong Qilu Stem Cells Engineering Co., Ltd.

Active Ingredients

Marketed Drugs (23)

abiraterone (zytiga) (2019)

aprepitant (Emend) (2020)

bortezomib (velcade) (2018)

carfilzomib (kyprolis) (2019)

cefazolin (ancef) (2015)

cefepime (maxipeme) (2016)

ceftriaxone (rocephin) (2016)

daptomycin (cubicin) (2021)

decitabine (dacogen) (2021)

exemestane (aromasin) (2020)

imatinib (gleevec) (2022)

irinotecan (Camptosar) (2016)

olanzapine (zyprexa) (2016)

olmesartan (benicar) (2019)

ondansetron (zofran) (2014)

oxaliplatin (eloxatin) (2016)

palonosetron (aloxi) (2018)

pemetrexed (alimta) (2017)

piperacillin (pipracil) (2018)

solifenacin (vesicare) (2018)

tadalafil (cialis) (2019)

tazobactam (Zosyn) (2018)

tenofovir (viread) (2018)

Drugs in Phase 4 Trials (1)

idebenone (1 trial)

Drugs in Phase 3 Trials (25)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (5 trials)

camrelizumab (1 trial)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (2 trials)

crizotinib (xalkori) (1 trial)

denosumab (prolia) (4 trials)

docetaxel (taxotere) (2 trials)

elagolix (orilissa) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

fluorouracil (efudex) (1 trial)

follitropin alfa (1 trial)

gemcitabine (gemzar) (1 trial)

leucovorin (1 trial)

norethindrone (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (3 trials)

pertuzumab (perjeta) (1 trial)

ql1203 (2 trials)

ql1209 (1 trial)

ql1604 (5 trials)

ql1706 (8 trials)

trastuzumab (herceptin) (2 trials)

vb4-845 (1 trial)

wx-0593 (3 trials)

Drugs in Phase 2 Trials (14)

apatinib (1 trial)

cend-1 (1 trial)

entecavir (baraclude) (1 trial)

etoposide (vepesid) (1 trial)

gefitinib (iressa) (2 trials)

meropenem (merrem) (2 trials)

piperacillin (pipracil) (1 trial)

psb205 (1 trial)

ql-007 (4 trials)

tazobactam (Zosyn) (1 trial)

tenofovir (viread) (3 trials)

toripalimab (1 trial)

umbilical cord mesenchymal stem cells (3 trials)

utd1 (1 trial)

Drugs in Phase 1 Trials (16)

capecitabine (xeloda) (1 trial)

filgrastim (neupogen) (1 trial)

fl058 (3 trials)

isosorbide (isordil) (1 trial)

panitumumab (vectibix) (1 trial)

qlf31907 (1 trial)

qlf32004 (1 trial)

qlh11811 (1 trial)

qlh11906 (1 trial)

qls1128 (1 trial)

qls31901 (1 trial)

qls31904 (1 trial)

qls31905 (1 trial)

ranibizumab (lucentis) (1 trial)

ritonavir (Norvir) (1 trial)

selatinib ditosilate (1 trial)

Drugs in Other Trials (5)

adalimumab (humira) (1 trial)

azathioprine (imuran) (1 trial)

montelukast (singulair) (2 trials)

prednisone (meticorten) (1 trial)

staphylococcal enterotoxin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Bone Marrow Diseases (Phase 3)

Bone Neoplasms (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 3)

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Liver Cirrhosis (Phase 2)

Lung Neoplasms (Phase 3)

Macular Degeneration (Phase 1)

Malnutrition (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Osteoporosis (Phase 3)

Osteoporosis, Postmenopausal (Phase 3)

Parkinson Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 63
  • # of Trial APIs: 61